You are here

Clinical Trials: Cord Blood

Comment

Discuss
Body: Conditions:   Leukemia;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome
Interventions:   Drug: Clofarabine/Busulfan x 4;   Procedure: Peripheral blood stem cell transplant;   Radiation: Total Lymphoid Irradiation
Sponsors:   University of Michigan Cancer Center;   Genzyme, a Sanofi Company
Completed
Body: Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Active, not recruiting - verified August 2017
Body: Condition:   Graft Versus Host Disease
Intervention:   Drug: Interleukin-2
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Novartis
Active, not recruiting
Body: Condition:   Epidermolysis Bullosa
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: hematopoietic bone marrow transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Body: Condition:   Inherited Immune Deficiencies
Interventions:   Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 1, 2016
Body: Conditions:   Sickle Cell Disease;   Beta Thalassemia
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
Sponsor:   Columbia University
Recruiting - verified July 2017
Body: Condition:   Hodgkin's Disease
Interventions:   Drug: Gemcitabine;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Antithymocyte Globulin;   Procedure: Allogeneic Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Filgrastim (G-CSF);   Drug: Methotrexate
Sponsor:   M.D. Anderson Cancer Center
Completed
Body: Conditions:   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Secondary Myelofibrosis
Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: Treg cell infusion;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Body: Conditions:   Breast Cancer;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Drug: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: radiation therapy;   Procedure: umbilical cord blood transplantation
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Completed
Body: Conditions:   Leukemia;   Myelodysplastic Syndromes;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Excess Blasts;   Refractory Anemia;   De Novo Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome
Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified June 2017
Body: Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: aldesleukin;   Biological: filgrastim;   Biological: natural killer cell (NK) therapy;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Procedure: Umbilical Cord Blood Transplantation (UCBT);   Radiation: Total body irradiation (TBI)
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Body: Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   MDS;   Refractory Anemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Non-Hodgkin's Lymphoma;   Leukemia;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting
Body: Conditions:   Congenital Amegakaryocytic Thrombocytopenia;   Diamond-blackfan Anemia;   Leukemia;   Myelodysplastic Syndromes;   Severe Congenital Neutropenia
Interventions:   Biological: alemtuzumab;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: methylprednisolone;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
Sponsors:   University of California, San Francisco;   National Cancer Institute (NCI)
Completed
Body: Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Biological: sargramostim;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: umbilical cord blood transplantation
Sponsors:   University of California, San Francisco;   National Cancer Institute (NCI)
Completed - verified September 2017
Body: Conditions:   Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
Intervention:   Procedure: umbilical cord blood transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated

Pages